NICE Technology Appraisal guidance (TA875 for semaglutide/Wegovy and TA664 for liraglutide/Saxenda) recommends these medications for weight management in adults with: A body mass index (BMI) of at least 35 kg/m and At least one weight-related comorbidity (such as type 2 diabetes, hypertension, dyslipidaemia, obstructive sleep apnoea, or non-alcoholic fatty liver disease) For liraglutide (Saxenda), NICE TA664 specifies additional criteria including prediabetes (HbA1c 42-47 mmol/mol or fasting plasma glucose 5.5-6.9 mmol/L) or high risk of cardiovascular disease
The protocol was approved by LondonWestminster Research Ethics Committee (REC Reference: 16/LO/1144)
PROMIS measures are available in many different languages, but these translations were developed and tested in the country where the language is natively spoken
The study included patients with type 2 diabetes who had an eGFR between 50 and 75 mL/min/1.73 m 2 and urine albumin to creatinine ratio above 33 and below 565 mg/mmol, or an eGFR between 25 and 50 mL/min/1.73 m 2 and urine albumin to creatinine ratio above 11.3 and below 565 mg/mmol
This comprehensive approach, combining dietary changes, physical activity, and lifestyle adjustments, provides a strong foundation for achieving and maintaining a healthy weight
